BioIVT completed the acquisition of XenoTech.

BioIVT, a provider of biospecimens, research models and services for drug and diagnostic development, completed the acquisition of XenoTech, a provider of products for ADME-Tox in vitro models and contract research services, from Sekisui Chemical, a plastics manufacturing company. Financial terms were not disclosed. "XenoTech has a well-established and excellent reputation for producing microsomes, subcellular fractions, and for designing and implementing ADME-Tox studies on a contract research basis. The XenoTech and BioIVT product portfolios are complementary, and when combined, will enable smarter science and accelerate medical breakthroughs that enhance and extend lives by delivering personalized biospecimen solutions to life science and diagnostic industries. We are also delighted to have this opportunity to expand our highly respected scientific team with the addition of experienced researchers from XenoTech," Dr. Richard Haigh, BioIVT CEO.